Home LiteratureArticle Details
PMID: 12132008 Published · ppublish English Journal Article

Controlling multidrug-resistant tuberculosis and access to expensive drugs: a rational framework.

Bulletin of the World Health Organization ·Vol. 80 ·No. 6 ·2002-00-00 ·Pages 489-95; discussion 495-500

Pablos-Mendez A, Gowda DK, Frieden TR

Abstract

The emergence and spread of multidrug-resistant tuberculosis (MDR-TB), i.e. involving resistance to at least isoniazid and rifampicin, could threaten the control of TB globally. Controversy has emerged about the best way of confronting MDR-TB in settings with very limited resources. In 1999, the World Health Organization (WHO) created a working group on DOTS-Plus, an initiative exploring the programmatic feasibility and cost-effectiveness of treating MDR-TB in low-income and middle-income countries, in order to consider the management of MDR-TB under programme conditions. The challenges of implementation have proved more daunting than those of access to second-line drugs, the prices of which are dropping. Using data from the WHO/International Union Against Tuberculosis and Lung Disease surveillance project, we have grouped countries according to the proportion of TB patients completing treatment successfully and the level of MDR-TB among previously untreated patients. The resulting matrix provides a reasonable framework for deciding whether to use second-line drugs in a national programme. Countries in which the treatment success rate, i.e. the proportion of new patients who complete the scheduled treatment, irrespective of whether bacteriological cure is documented, is below 70% should give the highest priority to introducing or improving DOTS, the five-point TB control strategy recommended by WHO and the International Union Against Tuberculosis and Lung Disease. A poorly functioning programme can create MDR-TB much faster than it can be treated, even if unlimited resources are available. There is no single prescription for controlling MDR-TB but the various tools available should be applied wisely. Firstly, good DOTS and infection control; then appropriate use of second-line drug treatment. The interval between the two depends on the local context and resources. As funds are allocated to treat MDR-TB, human and financial resources should be increased to expand DOTS worldwide.

MeSH Terms
Antitubercular Agents/economics,supply & distribution,therapeutic use Communicable Disease Control/economics Cost-Benefit Analysis Developing Countries/economics Drug Costs Drugs, Essential/economics,supply & distribution Health Care Rationing Health Priorities Health Services Accessibility/economics Humans National Health Programs/economics Treatment Outcome Tuberculosis, Multidrug-Resistant/drug therapy,epidemiology,prevention & control World Health Organization
Chemicals
Antitubercular Agents Drugs, Essential
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Pablos-Mendez Ariel
College of Physicians and Surgeons, Columbia University, New York, USA. [email protected]
Gowda Deepthiman K
Frieden Thomas R
Article Info
Journal
Bulletin of the World Health Organization
Abbr.
Bull World Health Organ
ISSN
0042-9686
Published
2002-00-00
Pages
489-95; discussion 495-500
Language
English
Region
Switzerland
NLM ID
7507052
PMCID
PMC2567530
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]